Pembrolizumab

TERMINATED · PHASE3 · Lung Neoplasms, Non-Small-Cell Lung Carcinoma

Business Reasons

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.